This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols

BackgroundThere are limited research and literature on the trial management challenges encountered in running adaptive platform trials. This trial design allows both (1) the seamless addition of new research comparisons when compelling clinical and scientific research questions emerge, and (2) early stopping of accrual to individual comparisons that do not show sufficient activity without affecting other active comparisons. Adaptive platform design trials also offer many potential benefits over traditional trials, from faster time to accrual to contemporaneously recruiting multiple research comparisons, added flexibility to focus on more promising research comparisons via pre-planned interim analyses and potentially shorter time to primary results. We share here our experiences from a trial management perspective, highlighting the challenges and successes.MethodsWe evaluated the operational aspects of making changes to these adaptive platform trials and identified both common and trial-specific challenges. The operational steps and challenges linked to both the addition of new research comparisons and stopping recruitment following pre-planned interim analysis were considered in our evaluation.ResultsSpecific operational challenges in these adaptive platform protocols, additional to those in traditional two-arm trials, were identified. Key lessons are presented describing some of the solutions and considerations over conducting these trials.Careful consideration on the practicality of the protocol structure (modular versus single protocol), the longevity and continuity of trial oversight committees, and having clear clinical and scientific criteria for the addition of new research comparisons were identified as some of the most common challenges.ConclusionsUnderstanding the operational complexities associated with running adaptive platform protocols is paramount for their conduct, adaptive platform trials offer an efficient model to run randomised controlled trials and we are continuing to work to reduce further the effort required from an operational perspective.Trial registrationFOCUS4: ISRCTN Registry, ISRCTN90061546. Registered on 16 October 2013. STAMPEDE: ISRCTN Registry, ISRCTN78818544. Registered on 2 February 2004.

[1]  M. Dimairo,et al.  Adaptive designs undertaken in clinical research: a review of registered clinical trials , 2016, Trials.

[2]  Babak Choodari-Oskooei,et al.  Measuring the impact of methodological research: a framework and methods to identify evidence of impact , 2014, Trials.

[3]  Noel W Clarke,et al.  Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial. , 2014, European urology.

[4]  M. Sydes,et al.  Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform. , 2016, European urology.

[5]  Sydes,et al.  A proposed charter for clinical trial data monitoring committees: helping them to do their job well , 2005, The Lancet.

[6]  M. Parmar,et al.  Prostate radiotherapy for men with metastatic disease: a new comparison in the STAMPEDE trial. , 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).

[7]  David Moher,et al.  SPIRIT 2013 Statement: defining standard protocol items for clinical trials. , 2015, Revista panamericana de salud publica = Pan American journal of public health.

[8]  M. Parmar,et al.  Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data , 2016, The Lancet. Oncology.

[9]  R. Butler,et al.  Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial , 2018 .

[10]  S. Berry,et al.  Efficiencies of platform clinical trials: A vision of the future , 2016, Clinical trials.

[11]  R. Laing,et al.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial , 2016, The Lancet.

[12]  Thomas Jaki,et al.  Some recommendations for multi-arm multi-stage trials , 2012, Statistical methods in medical research.

[13]  M. Sydes,et al.  Transdermal oestradiol as a method of androgen suppression for prostate cancer within the STAMPEDE trial platform , 2018, BJU international.

[14]  How Cancer Research UK is adapting to adaptive designs , 2011, Trials.

[15]  M. Parmar,et al.  More multiarm randomised trials of superiority are needed , 2014, The Lancet.

[16]  J. Woodcock,et al.  Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. , 2017, The New England journal of medicine.

[17]  D. Rennie,et al.  SPIRIT 2013 statement: defining standard protocol items for clinical trials. , 2013, Annals of internal medicine.

[18]  M. D. James,et al.  Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial , 2015, Journal of Clinical Pathology.

[19]  M. Parmar,et al.  Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial , 2012, Trials.

[20]  M. Parmar,et al.  Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols , 2017, Clinical trials.

[21]  D. Berry,et al.  A conceptual model for the development process of confirmatory adaptive clinical trials within an emergency research network , 2017, Clinical trials.